-
公开(公告)号：US20050014718A1
公开(公告)日：2005-01-20
申请号：US10487203
申请日：2002-08-20
IPC分类号： A23L1/305 , A61B20060101 , A61K31/70 , A61K38/17 , A61K38/36 , A61K38/45 , A61K39/00 , A61K39/385 , A61K39/39 , A61K39/395 , A61K47/36 , A61K47/48 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/04 , C07H3/06 , C07H5/06 , C07K1/22 , C07K2/00 , C07K16/18 , C07K16/32 , C12P21/08 , C12Q1/02 , G01N30/00 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/574 , A61K31/739
CPC分类号： A61K39/39558 , A61K38/1709 , A61K38/45 , A61K39/00 , A61K47/549 , A61K47/6851 , A61K2039/505 , C07H3/06 , C07K16/18 , C12Y204/00 , G01N33/57469 , G01N33/57492
摘要： The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.
摘要翻译： 本发明描述了由人肿瘤特异性表达的寡糖序列。 本发明涉及在生物样品中测定包含肿瘤特异性末端N-乙酰葡糖胺残基的寡糖序列的方法，所述样品中所述序列的存在是癌症存在的指示。 本发明提供包含多价形式的所述寡糖序列的抗原物质，并且还提供包含所述寡糖序列或与所述寡糖序列结合的物质的诊断试剂，药物组合物和癌症疫苗。 本发明还涉及治疗癌症的方法。
-
公开(公告)号：US08236487B2
公开(公告)日：2012-08-07
申请号：US10487203
申请日：2002-08-20
IPC分类号： C12Q1/00
CPC分类号： A61K39/39558 , A61K38/1709 , A61K38/45 , A61K39/00 , A61K47/549 , A61K47/6851 , A61K2039/505 , C07H3/06 , C07K16/18 , C12Y204/00 , G01N33/57469 , G01N33/57492
摘要： The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.
摘要翻译： 本发明描述了由人肿瘤特异性表达的寡糖序列。 本发明涉及在生物样品中测定包含肿瘤特异性末端N-乙酰葡糖胺残基的寡糖序列的方法，所述样品中所述序列的存在是癌症存在的指示。 本发明提供包含多价形式的所述寡糖序列的抗原物质，并且还提供包含所述寡糖序列或与所述寡糖序列结合的物质的诊断试剂，药物组合物和癌症疫苗。 本发明还涉及治疗癌症的方法。
-
公开(公告)号：US20060014672A1
公开(公告)日：2006-01-19
申请号：US10525011
申请日：2003-08-20
IPC分类号： A61K38/17 , A61K31/739
CPC分类号： A61K39/39558 , A61K38/1709 , A61K38/45 , A61K39/00 , A61K47/549 , A61K47/6851 , A61K2039/505 , C07H3/06 , C07K16/18 , C12Y204/00 , G01N33/57469 , G01N33/57492
摘要： The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.
摘要翻译： 本发明描述了由人肿瘤特异性表达的寡糖序列。 本发明涉及在生物样品中测定包含肿瘤特异性末端N-乙酰葡糖胺残基的寡糖序列的方法，所述样品中所述序列的存在是癌症存在的指示。 本发明提供包含多价形式的所述寡糖序列的抗原物质，并且还提供包含所述寡糖序列或与所述寡糖序列结合的物质的诊断试剂，药物组合物和癌症疫苗。 本发明还涉及治疗癌症的方法。
-
4.发明申请公开(公告)号：US20060014717A1
公开(公告)日：2006-01-19
申请号：US10518297
申请日：2003-06-30
申请人： Jonas Angstrom , Susann Teneberg , Juhani Saarinen , Tero Satomaa , Jari Natunen , Halina Miller-Podraza , Karl-Anders Karlsson , Maan Abul-Milh , Niamh Roche
发明人： Jonas Angstrom , Susann Teneberg , Juhani Saarinen , Tero Satomaa , Jari Natunen , Halina Miller-Podraza , Karl-Anders Karlsson , Maan Abul-Milh , Niamh Roche
IPC分类号： A61K39/02 , A61K31/739
CPC分类号： G01N33/56922 , A23L33/10 , A23L33/40 , A23V2002/00 , A61K31/702 , A61K45/06 , A61K47/61 , G01N33/566 , G01N33/56905 , G01N33/56911 , G01N33/56916 , Y02A50/473 , Y02A50/475 , A61K2300/00 , A23V2250/28 , A23V2200/32
摘要： The invention provides a therapeutical composition comprising purified fractions of compounds being or containing a pathogen-inhibiting oligosaccharide sequence for use as a medicament. The present invention especially describes an oligosaccharide-containing substance or receptor binding to diarrheagenic Escherichia coli and/or zoonotic Helicobacter species, and use thereof in, e.g., pharmaceutical, nutritional and other compositions for prophylaxis and treatment of conditions due to the presence of Escherichia coli and/or zoonotic Helicobacter species. The invention is also directed to the use of the receptors for diagnostics of Escherichia coli and/or zoonotic Helicobacter species.
摘要翻译： 本发明提供包含纯化的化合物组分的治疗组合物，所述化合物是或含有用作药物的病原体抑制性寡糖序列。 本发明特别描述了结合腹泻大肠杆菌和/或人畜共患的幽门螺杆菌物种的含寡糖的物质或受体及其在例如药物，营养和其它组合物中的用途，用于预防和治疗由于大肠杆菌的存在而引起的病症 和/或人畜共患的幽门螺杆菌属物种。 本发明还涉及用于诊断大肠杆菌和/或人畜共患的幽门螺杆菌属物种的受体。
-
公开(公告)号：US20060122148A1
公开(公告)日：2006-06-08
申请号：US10533877
申请日：2003-11-06
IPC分类号： A61K31/739 , C08B37/00
CPC分类号： A61Q17/005 , A61K8/68 , A61K8/73 , A61K31/7012 , A61K31/702 , A61K31/7032 , A61K31/715 , A61K39/105 , A61Q5/02 , A61Q11/00 , A61Q19/00 , A61Q19/10 , C08B37/006
摘要： The present invention describes an oligosaccharide substance or receptor binding to Helicobacter pylori, and the use thereof in, e.g., pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori.
摘要翻译： 本发明描述了结合幽门螺杆菌的寡糖物质或受体，以及其在例如药物和营养组合物中用于治疗幽门螺杆菌存在的病症的用途。 本发明还涉及该受体用于诊断幽门螺杆菌的用途。
-
公开(公告)号：US20050220819A1
公开(公告)日：2005-10-06
申请号：US10501786
申请日：2003-01-20
申请人： Halina Miller-Podraza , Susann Teneberg , Jonas Angstrom , Karl-Anders Karlsson , Jari Natunen , Jari Helin
发明人： Halina Miller-Podraza , Susann Teneberg , Jonas Angstrom , Karl-Anders Karlsson , Jari Natunen , Jari Helin
IPC分类号： A23L1/30 , A61K9/10 , A61K31/702 , A61K31/7028 , A61K31/715 , A61K31/726 , A61K39/00 , A61K47/48 , A61P1/04 , A61P1/16 , A61P1/18 , A61P7/06 , A61P9/00 , A61P17/00 , A61P31/04 , A61P35/00 , A61P37/00 , A61P37/02 , C07H3/02 , C07H5/06 , C08B37/00 , C12P19/26 , C12Q1/02 , C12R1/01 , C07K14/195 , A61K39/02
CPC分类号： A61K31/726 , A61K31/702 , A61K31/7028 , A61K31/715
摘要： The present application describes a binding epitope to Helicobacter pylori, namely substances comprising the oligosaccharide sequence -Gal(Nac)r2$g(b)4Glc(A)q2(Nac)r3-, and the use thereof in pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori in a subject, e.g. gastritis, gastric ulcers, gastric adenocarcinoma, liver disease, pancreatic disease, skin disease, heart disease, autoimmune diseases and sudden infant death syndrome. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori, to a method of producing chondroitin oligosaccharides from chondroitin sulphates, and a method for production of amidated glucuronic acid comprising oligosaccharides and monosaccharides from glucuronic acid comprising polysaccharides.
摘要翻译： 本申请描述了幽门螺旋杆菌的结合表位，即包含寡糖序列的物质 - （G）（b）4Glc（A）Q2（Nac） 和其在药物和营养组合物中的用途，用于治疗由于幽门螺杆菌在受试者中的存在而引起的病症，例如 胃炎，胃溃疡，胃腺癌，肝病，胰腺疾病，皮肤病，心脏病，自身免疫性疾病和婴儿猝死综合征。 本发明还涉及用于诊断幽门螺杆菌的用途，用于从硫酸软骨素生产软骨素寡糖的方法，以及包含寡糖和包含多糖的葡糖醛酸的单糖的酰胺化葡糖醛酸的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.026 秒)
